HC Wainwright restated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at $0.59 EPS.
Gossamer Bio Trading Up 3.1 %
Shares of GOSS stock opened at $0.99 on Thursday. The firm has a market capitalization of $225.15 million, a PE ratio of -3.11 and a beta of 1.81. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The stock has a fifty day moving average of $0.87 and a two-hundred day moving average of $0.90. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.60.
Gossamer Bio (NASDAQ:GOSS – Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million. As a group, research analysts expect that Gossamer Bio will post -0.28 EPS for the current year.
Hedge Funds Weigh In On Gossamer Bio
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Recommended Stories
- Five stocks we like better than Gossamer Bio
- Energy and Oil Stocks Explained
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- How to Calculate Options Profits
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.